Lab studies suggest that the Pfizer–BioNTech and Moderna COVID-19 vaccines are significantly less effective in providing antibody protection against the 501.V2 variant…
Lab studies suggest that the Pfizer–BioNTech and Moderna COVID-19 vaccines are significantly less effective in providing antibody protection against the 501.V2 variant of the disease, which is most prevalent in South Africa.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan to read this report and the complete Premium retrospective archive.
HealthLab studies suggest that the Pfizer–BioNTech and Moderna COVID-19 vaccines are significantly less effective in providing antibody protection against the 501.V2 variant…
View Premium plansBrowse free archive reportsLab studies suggest that the Pfizer–BioNTech and Moderna COVID-19 vaccines are significantly less effective in providing antibody protection against the 501.V2 variant of the disease, which is most prevalent in South Africa.